fashion -WSS

fashion

author：leisure time 2025-09-06 03:28:10 - browse：5456

Jakub Porzycki/NurPhoto via AP

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the fallout from Pfizer’s downbeat update, a new entrant in obesity research, and an orthogonal CRISPR business.

The need-to-know this morning

Apellis Pharmaceuticals said a European advisory committee is expected to recommend against the approval of Syfovre, its eye drug for a common form of blindness. The company plans to appeal the negative ruling.
Sage Therapeutics and Biogen announced the commercial launch of Zurzuvae, an oral treatment for women with postpartum depression.
Merck and Moderna reported three-year follow-up data on their mRNA-based immunotherapy for advanced melanoma. Phase 3 studies are underway.
The FDA accepted Amgen’s marketing application for tarlatamab, a bispecific antibody to treat advanced small cell lung cancer. The approval decision date is June 12, 2024.

Is it time to worry about Moderna?

Yesterday’s news that Pfizer is expecting to sell far fewer Covid-19 vaccines than Wall Street expected sent shares of Moderna down as much as 6% on fears that the company could be in for a painful revision of its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： He's a Nobel laureate. Critics say he was misleading on Covid

knowledge

WSS

Apple Vision Pro: A first look at health apps on the new VR headset

Medicare inequities exacerbate Puerto Rico’s health disparities

Vertigo drug brings hope for rare neuron disorder, Niemann

Congressmen charge Covid hearing ‘could have been an email’

Why palliative psychiatry is worth discussing

Even great ERs can’t make up for American health disparities

hotspot

fashion

The need-to-know this morning

Is it time to worry about Moderna?

knowledge

New air purifier tech could be key to improving indoor air quality

A new nitrogen execution bill also undermines medical licensing

Anesthesiologist group: stop taking Ozempic before surgery

Alabama hospital puts IVF treatments on hold

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

At least 13 dead in Texas as scorching temps continue

In utero gene editing: an explainer

The high cost of giving birth even with insurance

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

explore

Biden administration opens offers in Medicare drug price negotiations

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Vertigo drug brings hope for rare neuron disorder, Niemann

Dario to buy mental health app maker Twill in cash and stock deal

Congressmen charge Covid hearing ‘could have been an email’

Antivenom research: Lessons from HIV applied in search for universal antidote

leisure time

knowledge

explore

focus